Cargando…

Evaluation of risk adjustment performance of diagnosis-based and medication-based comorbidity indices in patients with chronic obstructive pulmonary disease

OBJECTIVES: This study assessed risk adjustment performance of six comorbidity indices in two categories of comorbidity measures: diagnosis-based comorbidity indices and medication-based ones in patients with chronic obstructive pulmonary disease (COPD). METHODS: This was a population–based retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo Ie, Huei, Tang, Chao-Hsiun, Sheu, Mei-Ling, Liu, Hung-Yi, Lu, Ning, Tsai, Tuan-Ya, Chen, Bi-Li, Huang, Kuo-Cherh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269939/
https://www.ncbi.nlm.nih.gov/pubmed/35802678
http://dx.doi.org/10.1371/journal.pone.0270468
_version_ 1784744344205393920
author Guo Ie, Huei
Tang, Chao-Hsiun
Sheu, Mei-Ling
Liu, Hung-Yi
Lu, Ning
Tsai, Tuan-Ya
Chen, Bi-Li
Huang, Kuo-Cherh
author_facet Guo Ie, Huei
Tang, Chao-Hsiun
Sheu, Mei-Ling
Liu, Hung-Yi
Lu, Ning
Tsai, Tuan-Ya
Chen, Bi-Li
Huang, Kuo-Cherh
author_sort Guo Ie, Huei
collection PubMed
description OBJECTIVES: This study assessed risk adjustment performance of six comorbidity indices in two categories of comorbidity measures: diagnosis-based comorbidity indices and medication-based ones in patients with chronic obstructive pulmonary disease (COPD). METHODS: This was a population–based retrospective cohort study. Data used in this study were sourced from the Taiwan National Health Insurance Research Database. The study population comprised all patients who were hospitalized due to COPD for the first time in the target year of 2012. Each qualified patient was individually followed for one year starting from the index date to assess two outcomes of interest, medical expenditures within one year after discharge and in-hospital mortality of patients. To assess how well the added comorbidity measures would improve the fitted model, we calculated the log-likelihood ratio statistic G(2). Subsequently, we compared risk adjustment performance of the comorbidity indices by using the Harrell c-statistic measure derived from multiple logistic regression models. RESULTS: Analytical results demonstrated that that comorbidity measures were significant predictors of medical expenditures and mortality of COPD patients. Specifically, in the category of diagnosis-based comorbidity indices the Elixhauser index was superior to other indices, while the RxRisk-V index was a stronger predictor in the framework of medication-based codes, for gauging both medical expenditures and in-hospital mortality by utilizing information from the index hospitalization only as well as the index and prior hospitalizations. CONCLUSIONS: In conclusion, this work has ascertained that comorbidity indices are significant predictors of medical expenditures and mortality of COPD patients. Based on the study findings, we propose that when designing the payment schemes for patients with chronic diseases, the health authority should make adjustments in accordance with the burden of health care caused by comorbid conditions.
format Online
Article
Text
id pubmed-9269939
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-92699392022-07-09 Evaluation of risk adjustment performance of diagnosis-based and medication-based comorbidity indices in patients with chronic obstructive pulmonary disease Guo Ie, Huei Tang, Chao-Hsiun Sheu, Mei-Ling Liu, Hung-Yi Lu, Ning Tsai, Tuan-Ya Chen, Bi-Li Huang, Kuo-Cherh PLoS One Research Article OBJECTIVES: This study assessed risk adjustment performance of six comorbidity indices in two categories of comorbidity measures: diagnosis-based comorbidity indices and medication-based ones in patients with chronic obstructive pulmonary disease (COPD). METHODS: This was a population–based retrospective cohort study. Data used in this study were sourced from the Taiwan National Health Insurance Research Database. The study population comprised all patients who were hospitalized due to COPD for the first time in the target year of 2012. Each qualified patient was individually followed for one year starting from the index date to assess two outcomes of interest, medical expenditures within one year after discharge and in-hospital mortality of patients. To assess how well the added comorbidity measures would improve the fitted model, we calculated the log-likelihood ratio statistic G(2). Subsequently, we compared risk adjustment performance of the comorbidity indices by using the Harrell c-statistic measure derived from multiple logistic regression models. RESULTS: Analytical results demonstrated that that comorbidity measures were significant predictors of medical expenditures and mortality of COPD patients. Specifically, in the category of diagnosis-based comorbidity indices the Elixhauser index was superior to other indices, while the RxRisk-V index was a stronger predictor in the framework of medication-based codes, for gauging both medical expenditures and in-hospital mortality by utilizing information from the index hospitalization only as well as the index and prior hospitalizations. CONCLUSIONS: In conclusion, this work has ascertained that comorbidity indices are significant predictors of medical expenditures and mortality of COPD patients. Based on the study findings, we propose that when designing the payment schemes for patients with chronic diseases, the health authority should make adjustments in accordance with the burden of health care caused by comorbid conditions. Public Library of Science 2022-07-08 /pmc/articles/PMC9269939/ /pubmed/35802678 http://dx.doi.org/10.1371/journal.pone.0270468 Text en © 2022 Guo Ie et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Guo Ie, Huei
Tang, Chao-Hsiun
Sheu, Mei-Ling
Liu, Hung-Yi
Lu, Ning
Tsai, Tuan-Ya
Chen, Bi-Li
Huang, Kuo-Cherh
Evaluation of risk adjustment performance of diagnosis-based and medication-based comorbidity indices in patients with chronic obstructive pulmonary disease
title Evaluation of risk adjustment performance of diagnosis-based and medication-based comorbidity indices in patients with chronic obstructive pulmonary disease
title_full Evaluation of risk adjustment performance of diagnosis-based and medication-based comorbidity indices in patients with chronic obstructive pulmonary disease
title_fullStr Evaluation of risk adjustment performance of diagnosis-based and medication-based comorbidity indices in patients with chronic obstructive pulmonary disease
title_full_unstemmed Evaluation of risk adjustment performance of diagnosis-based and medication-based comorbidity indices in patients with chronic obstructive pulmonary disease
title_short Evaluation of risk adjustment performance of diagnosis-based and medication-based comorbidity indices in patients with chronic obstructive pulmonary disease
title_sort evaluation of risk adjustment performance of diagnosis-based and medication-based comorbidity indices in patients with chronic obstructive pulmonary disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269939/
https://www.ncbi.nlm.nih.gov/pubmed/35802678
http://dx.doi.org/10.1371/journal.pone.0270468
work_keys_str_mv AT guoiehuei evaluationofriskadjustmentperformanceofdiagnosisbasedandmedicationbasedcomorbidityindicesinpatientswithchronicobstructivepulmonarydisease
AT tangchaohsiun evaluationofriskadjustmentperformanceofdiagnosisbasedandmedicationbasedcomorbidityindicesinpatientswithchronicobstructivepulmonarydisease
AT sheumeiling evaluationofriskadjustmentperformanceofdiagnosisbasedandmedicationbasedcomorbidityindicesinpatientswithchronicobstructivepulmonarydisease
AT liuhungyi evaluationofriskadjustmentperformanceofdiagnosisbasedandmedicationbasedcomorbidityindicesinpatientswithchronicobstructivepulmonarydisease
AT luning evaluationofriskadjustmentperformanceofdiagnosisbasedandmedicationbasedcomorbidityindicesinpatientswithchronicobstructivepulmonarydisease
AT tsaituanya evaluationofriskadjustmentperformanceofdiagnosisbasedandmedicationbasedcomorbidityindicesinpatientswithchronicobstructivepulmonarydisease
AT chenbili evaluationofriskadjustmentperformanceofdiagnosisbasedandmedicationbasedcomorbidityindicesinpatientswithchronicobstructivepulmonarydisease
AT huangkuocherh evaluationofriskadjustmentperformanceofdiagnosisbasedandmedicationbasedcomorbidityindicesinpatientswithchronicobstructivepulmonarydisease